"We are pleased to see that the data from this extension study
of ALN-VSP further validates the longer-term safety and
tolerability of Tekmira's LNP technology. Tekmira's
industry-leading LNP delivery platform is enabling the anti-tumor
activity reported in this study and the development of a number of
RNAi products currently in clinical trials," said Dr. Mark J.
Murray, Tekmira's President and CEO.

The most recent ALN-VSP data were presented at the American
Society of Clinical Oncology (ASCO) meeting in a poster titled
"Open-label extension study of the RNAi therapeutic ALN-VSP02 in
cancer patients responding to therapy." Alnylam disclosed that,
overall, the results demonstrated disease control lasting more than
six months in the majority of patients treated on the extension
study, including a complete response (CR) in an endometrial cancer
patient who had multiple liver metastases. In this study, chronic
dosing of up to 23 months with ALN-VSP was found to be generally
safe and well tolerated.

For more detailed information about the Phase 1 data for
ALN-VSP, please refer to the Alnylam news release dated June 4,
2012, which can be found on Alnylam's website at
www.alnylam.com.

Tekmira's LNP technology is enabling the systemic RNAi product
pipeline of Alnylam Pharmaceuticals, including the products
ALN-VSP, ALN-TTR and ALN-PCS.

About RNAi and Tekmira's LNP Technology

RNAi therapeutics have the potential to treat a broad number of
human diseases by "silencing" disease causing genes. The
discoverers of RNAi, a gene silencing mechanism used by all cells,
were awarded the 2006 Nobel Prize for Physiology or Medicine. RNAi
therapeutics, such as "siRNA," require delivery technology to be
effective systemically.
Tekmira believes its LNP technology represents the most widely
adopted delivery technology for the systemic delivery of RNAi
therapeutics.
Tekmira's LNP platform is being utilized in multiple clinical
trials by both Tekmira and its partners. Tekmira's LNP technology
(formerly referred to as stable nucleic acid-lipid particles or
SNALP) encapsulates siRNAs with high efficiency in uniform lipid
nanoparticles that are effective in delivering RNAi therapeutics to
disease sites in numerous preclinical models. Tekmira's LNP
formulations are manufactured by a proprietary method which is
robust, scalable and highly reproducible, and LNP-based products
have been reviewed by multiple FDA divisions for use in clinical
trials. LNP formulations comprise several lipid components that can
be adjusted to suit the specific application.

About Tekmira

Tekmira Pharmaceuticals Corporation is a biopharmaceutical
company focused on advancing novel RNAi therapeutics and providing
its leading lipid nanoparticle delivery technology to
pharmaceutical partners.
Tekmira has been working in the field of nucleic acid delivery for
over a decade and has broad intellectual property covering LNPs.
Further information about Tekmira can be found at
www.tekmirapharm.com. Tekmira is based in Vancouver, B.C.

The Tekmira Pharmaceuticals logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=8319

Tekmira Forward-looking Statements and Information

This press release contains "forward-looking statements" or
"forward-looking information" within the meaning of applicable
securities laws (collectively, "forward-looking statements").
Forward-looking statements are generally identifiable by use of the
words "believes," "may," "plans," "will," "anticipates,"
"intends,"
"budgets," "could," "estimates," "expects," "forecasts," "projects"
and similar expressions, and the negative of such
expressions.
Forward-looking statements in this news release include statements
about Tekmira's strategy, future operations, clinical trials,
prospects and the plans of management; RNAi (ribonucleic acid
interference) product development programs; data from an extension
study of a Phase 1 human clinical trial with ALN-VSP conducted by
Alnylam; Alnylam's ALN-VSP product development program as a
treatment for cancer; the advancement of products that utilize
Tekmira's lipid nanoparticle technology; expectations regarding the
advancement of multiple product candidates; the quantum and timing
of further clinical data being presented for LNP-enabled products;
continued innovation and protection of LNP technology; timing of
the initiation of clinical trials and release of clinical data from
Tekmira's product candidates; the quantum and timing of potential
funding; and the use of lipid nanoparticle technology by Tekmira's
licensees.

With respect to the forward-looking statements contained in this
news release, Tekmira has made numerous assumptions regarding,
among other
things: LNP's status as a leading RNAi delivery technology; early
results in human clinical trials are indicative of the potential
opportunity to treat a variety of disease indications; Tekmira's
research and development capabilities and resources; the timing and
results of clinical data releases and use of LNP technology by
Tekmira's development partners and licensees; the time required to
complete research and product development activities; the timing
and quantum of payments to be received under contracts with
Tekmira's collaborative partners including Alnylam; and the
sufficiency of budgeted capital expenditures in carrying out
planned activities. While Tekmira considers these assumptions to be
reasonable, these assumptions are inherently subject to significant
business, economic, competitive, market and social uncertainties
and contingencies.

Additionally, there are known and unknown risk factors which
could cause Tekmira's actual results, performance or achievements
to be materially different from any future results, performance or
achievements expressed or implied by the forward-looking statements
contained herein. Known risk factors include, among others: the
possibility that current and future data from the human clinical
trials with ALN-VSP conducted by Alnylam does not and will not lead
to favourable results for Tekmira's products or prospects; the
possibility that there will not be further clinical data on
LNP-enabled products in the quantum nor timing anticipated by
Tekmira, or at all; the possibility that Tekmira may not be able to
innovate nor protect its LNP technology; the possibility that other
organizations have made advancements in RNAi delivery technology
that Tekmira is not aware of; the FDA will not approve the
commencement of Tekmira's planned clinical trials or approve the
use of Tekmira's products; difficulties, delays or inaccuracies in
the progress, timing, results and data from clinical trials and
studies; the possibility that Tekmira may not advance any further
product candidates; competition from other pharmaceutical or
biotechnology companies; Tekmira's development partners and
licensees conducting clinical trials and development programs will
not result in expected results on a timely basis, or at all;
anticipated payments under contracts with Tekmira's collaborative
partners will not be received by Tekmira on a timely basis, or at
all, or in the quantum expected by Tekmira; IND applications may
not be filed on a timely basis, pre-clinical trials may not be
completed, or clinical trials started, when anticipated or at all;
pre-clinical or clinical trials may not generate results that
warrant future development of the tested drug candidate; funding
from research and product development partners may not be provided
when required under agreements with those partners; and Tekmira has
not sufficiently budgeted for capital expenditures necessary to
carry out planned activities.

A more complete discussion of the risks and uncertainties facing
Tekmira appears in Tekmira's Annual Report on Form 20-F for the
year ended December 31, 2011, which is available at www.sedar.com
or at www.sec.gov/edgar. All forward-looking statements herein are
qualified in their entirety by this cautionary statement, and
Tekmira disclaims any obligation to revise or update any such
forward-looking statements or to publicly announce the result of
any revisions to any of the forward-looking statements contained
herein to reflect future results, events or developments, except as
required by law.

Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment.